Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice TargetHot
Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $150 to $158.
Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $150 to $158.